XClose

Euro Ewing Consortium

International Clinical Trials to Improve Survival from Ewing Sarcoma
Menu

Euro Ewing 2012 – Information for patients and carers

The aim of the Euro Ewing 2012 trial is to compare different chemotherapy regimens to determine which is more effective and/or has fewer side effects.

Why is this trial being run?

The trial is comparing two treatments, known as treatment arms A and B.

Treatment arm A is the chemotherapy that is the standard treatment used in Europe whereas treatment arm B is the chemotherapy that is used in the USA. The trial is being run as we do not know which treatment is best.

A second reason for running the trial is to test if a drug called zoledronic acid can improve treatment for Ewing sarcoma. Zoledronic acid has been widely used for the treatment of other bone diseases and cancers that start in or spread to the bone, so we think that it may offer benefit for patients with Ewing sarcoma without worsening the side effects of the chemotherapy. We do not know whether this is the best treatment for patients with Ewing sarcoma.

Can I take part in the trial?

If you have been recently diagnosed with Ewing sarcoma for the first time, you may be able to take part in the trial. Your doctor will explain whether you are able to take part. Your doctor will review your diagnostic tests and medical notes to see if you are eligible to take part in the trial.

What treatment will I receive?

Treatment arm A

In the first part of the trial, if you are given treatment arm A you will receive a type of chemotherapy called VIDE, followed by surgery and/or radiotherapy, then more chemotherapy.

After surgery and/ or radiotherapy, you will have the opportunity to take part in the second part of the trial which tests zoledronic acid.

The doctors will see how well you have responded to the treatment so far and then decide which treatment would be best for you. You will receive either VAC or VAI chemotherapy. At the same time as receiving VAC or VAI, half of the patients will receive zoledronic acid. You may be in the group that receives zoledronic acid.

Treatment arm B

If you are given treatment arm B you will receive a type of chemotherapy called VDC/IE, followed by surgery and/or radiotherapy, then more chemotherapy.

After surgery and/ or radiotherapy, you will have the opportunity to take part in the second part of the trial.

You will receive IE/VC chemotherapy. At the same time as receiving IE/VC, half of the patients will also receive zoledronic acid. You may be in the group that receives zoledronic acid.

For more detailed information, please go to the following websites:

Country Website
UK Cancer Research UK
Spain Registro espanol de estudios clinicos

Can I choose which treatment arm I receive?

No. Euro Ewing 2012 is a randomised trial so you will be randomly assigned to a treatment arm by a computer. This is done so that neither you or your doctor will be able to influence which treatment arm you receive and means that the results of the trial are not biased in any way.

Where is the trial running?

At present (September 2015), the trial is recruiting patients at hospitals in the following locations and will open in other countries outside of the UK, Spain and France over the next months:

UK

Aberdeen Royal Aberdeen Children's Hospital
Belfast  Belfast Hospital for Sick Children
Birmingham Birmingham Children’s Hospital
Birmingham
Queen Elizabeth Hospital, Birmingham
Bristol Bristol Royal Hospital for Children
Bristol
 Bristol Haematology and Oncology
Cambridge
Addenbrooke's Hospital
Cardiff Children’s Hospital for Wales, Cardiff
Edinburgh Royal Hospital for Sick Children, Edinburgh
Glasgow Royal Hospital for Sick Children, Glasgow
Leeds
Leeds General Infirmary
Leeds
St James's University Hospital
Leicester
Leicester General Infirmary
Liverpool Alder Hey Children's Hospital, Liverpool
London Great Ormond Street Hospital
London University College London Hospital
Manchester Royal Manchester Children's Hospital
Manchester The Christie Hospital, Manchester
Newcastle Royal Victoria Infirmary, Newcastle
Nottingham Queen's Medical Centre, Nottingham
Nottingham Nottingham City Hospital
Oxford  Oxford John Radcliffe Hospital
Sheffield  Sheffield Children's Hospital
Sheffield  Weston Park Hospital, Sheffield
Southampton  Southampton General Hospital
Sutton  Royal Marsden Hospital (paediatrics)

Spain

Barakaldo

Hospital De Cruces

Barcelona
Hospital De La Sant Creu I Sant Paul
Barcelona Hospital Universitari Vall D'hebron
Barcelona Institut Catala D'oncologia (ico) Hospitalet 
Madrid Grupo Espanol De Investigacion En Sarcomas
Madrid
Hospital Del Nino Jesus
Madrid
Hospital La Paz
Madrid
Hospital Puerta De Hierro
Madrid
Hospital Universitario Gregorio Maranon
Malaga

Hospital Regional Universitario de Málaga

Malaga 
Hospital Clinico Virgen De La Victoria
Palma De Mallorca
Hospital Son Espases
Oviedo Hospital Central De Asturias
Seville
Hospital Virgen del Rocío
Tenerife
Hospital Canarias
Valencia
Hospital Politecnico U La Fe
Zaragoza 
Hospital Miguel Servet

France

Lyon Centre Leon Berard
Nantes
Centre Hospitalier Universitaire De Nantes
Rennes
Centre Hospitalier Universitaire De Rennes - Hopital Sud
Vandœuvre-lès-Nancy
Institut De Cancerologie De Lorraine - Alexis Vautrin

How many patients will take part?

600 patients will be recruited from across Europe between 2013 and 2018.

How can I find out more information?

How can I take part in the trial?

Talk about the trial with your doctor who will find out if you are eligible and if so, help you to take part.

If you have any questions about this trial, please contact the Cancer Research UK Clinical Trials Unit at the University of Birmingham ee2012@trials.bham.ac.uk
***The Trial Office cannot give advice on personal clinical questions***